

#2 Attachment 1

PTO/SB/08 (2-92)

Sheet 1 of 3

| | | |
|--|---|-------------------------------|
| Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i> | Docket Number 273012011100 | Application Number 09/556,833 |
| | Applicant Patrick Mark CURRY, et al. | |
| | Filing Date: April 21, 2000 | Group Art Unit 1614 |
| | Mailing Date March 20, 2001 | |

U.S. PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Filing Date If Appropriate |
|-------------------|----------|---------|--------------|------------------|-------|----------|----------------------------|
| mm | 1. | 12/1992 | 5,171,749 | Levy et al. | 514 | 410 | |
| | 2. | 06/1999 | 5,929,105 | Sternberg et al | 514 | 410 | |
| | 3. | 03/1984 | 4,436,727 | Ribi | 424 | 177 | |
| | 4. | 09/1989 | 4,866,034 | Ribi | 514 | 2 | |
| | 5. | 03/1990 | 4,912,094 | Myers et al. | 514 | 54 | |
| | 6. | 04/1990 | 4,920,143 | Levy et al. | 514 | 410 | |
| | 7. | 11/1989 | 4,883,790 | Levy et al. | 540 | 145 | |
| | 8. | 03/1992 | 5,095,030 | Levy et al. | 514 | 410 | |
| | 9. | 03/1999 | 5,880,145 | Sternberg et al. | 514 | 410 | |
| | 10. | 05/1994 | 5,308,608 | Dolphin et al. | 424 | 9 | |
| | 11. | 04/1995 | 5,405,957 | Tang et al. | 540 | 472 | |
| | 12. | 04/1996 | 5,512,675 | Tang et al. | 540 | 472 | |
| | 13. | 03/1998 | 5,726,304 | Tang et al. | 540 | 145 | |
| | 14. | 12/1992 | 5,171,741 | Dougherty | 514 | 185 | |
| | 15. | 11/1998 | 5,831,088 | Dolphin et al. | 540 | 474 | |
| | 16. | 12/1997 | 5,703,230 | Boyle et al. | 540 | 145 | |
| | 17. | 03/1999 | 5,883,246 | Bruckner et al. | 540 | 145 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Country | Class | Subclass | Translation YES NO |
|-------------------|----------|------|--------------|---------|-------|----------|--------------------|
|-------------------|----------|------|--------------|---------|-------|----------|--------------------|

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

| Examiner Initials | Ref. No. | Title |
|-------------------|----------|--|
| mm | 18. | Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD (1996) Hematologic effects of flt3 ligand <i>in vivo</i> in mice. <i>Blood</i> 88:2004-2012 |

EXAMINER:

Maurice

DATE CONSIDERED:

8-81-01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 273012011100

Application Number 09/556,833

Applicant

Patrick Mark CURRY, et al.

Filing Date: April 21, 2000

Group Art Unit 1614

Mailing Date March 20, 2001

- mm
19. Burger, U.L., Chang, M.P., Nagoshi, M., Goedegebuure, P.S. and Eberlein, T.J. (1996) Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro. *Annals of Surgical Oncology*, 3:580-587.
 20. Chen, W.R., Adams, R.L., Carubelli, R. and Nordquist, R.E. (1997) Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment. *Cancer Letters*, 115:25-30.
 21. Cho, Y.H., Straight, R.C. and Smith, J.A., Jr. (1992) Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model. *J Urol*, 147:743-6.
 22. Cox, J.C. and Coulter, A.R. (1997) Adjuvants--a classification and review of their modes of action. *Vaccine*, 15:248-56.
 23. Dougherty, T.J., Grindley, G.B., Fiel, R., Weishaupt, K.R. and Boyle, D.G. (1975) Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. *Journal of the National Cancer Institute*, 55:115-119.
 24. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR (1998) FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. *Cancer Res* 58:380-383.
 25. Evans, S., Matthews, W., Perry, R., Fraker, D., Norton, J. and Pass, H.I. (1990) Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. *Journal of the National Cancer Institute*, 82:34-39.
 26. Fingar, V.H., Wieman, T.J. and Doak, K.W. (1990) Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. *Cancer Research*, 50:2599-2603.
 27. Gore, M. and Riches, P. (1996) The history of immunotherapy. In Gore, M. and Riches, P. (eds.), *Immunotherapy in cancer*. John Wiley & Sons, Chichester, pp. 1-9.
 28. Granville, D.J., Levy, J.G. and Hunt, D.W. (1998) Photodynamic treatment with benzoporphyrin derivative monoacid ring A produces protein tyrosine phosphorylation events and DNA fragmentation in murine P815 cells. *Photochem Photobiol*, 67:358-62.
 29. Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD (1995) The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells *in vitro*: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. *J Exp Med* 181:1357-1363.
 30. Korbelik, M., Kros, G. and Chaplin, D.J. (1993) Can PDT be potentiated by immunotherapy. *Proc. SPIE*, 1616:192-198.
 31. Korbelik M: Induction of tumor immunity by photodynamic therapy. *J Clin Laser Med Surg* (1996) 14:329-334.
 32. Korbelik, M., Naraparaju, V.R. and Yamamoto, N. (1997) Macrophage-directed immunotherapy as

EXAMINER:

DATE CONSIDERED:

3-31-01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 273012011100

Application Number 09/556,833

Applicant

Patrick Mark CURRY, et al.

Filing Date: April 21, 2000

Group Art Unit 1614

Mailing Date March 20, 2001

- mt*
33. adjuvant to photodynamic therapy of cancer. *British Journal of Cancer*, 75:202-7.
34. Korbely, M. and Cecic, I. (1998) Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. *J Photochem Photobiol B*, 44:151-8.
35. Krosi, G. and Korbely, M. (1994) Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). *Cancer Letters*, 84:43-49.
36. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. *J Exp Med* 184:1953-1962.
37. Myers, R.C., Lau, B.H., Kunihiro, D.Y., Torrey, R.R., Woolley, J.L. and Tosk, J. (1989) Modulation of hematoporphyrin derivative-sensitized phototherapy with corynebacterium parvum in murine transitional cell carcinoma. *Urology*, 33:230-235.
38. Nseyo, U.O., Whalen, R.K., Duncan, M.R., Berman, B. and Lundahl, S. (1989) Immune response following photodynamic therapy for bladder cancer. *Proceedings of the Society of Photo-Optical Instrumentation Engineers*, 1065:66-72.
39. Section 3: Treatment of metastatic cancer to bone. In DeVita Jr., V.T., Hellman, S. and Rosenberg, S.A. (eds.), *Cancer: Principles and Practice*. J.B. Lippincott Company, Philadelphia, Vol. 2, pp. 2298-2317.

EXAMINER:

DATE CONSIDERED:

3-31-01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.